

GENETIC SIGNATURES RESPONDS TO THE BCAL DIAGNOSTICS ANNOUNCEMENT

Genetic Signatures Limited (ASX: GSS) refers to the announcement released today by BCAL Diagnostics Limited (ASX: BDX) entitled “BCAL acquires shares in Genetic Signatures”.

The Company confirms that it was not notified in advance of BCAL’s announcement and had no prior knowledge of the proposed acquisition of shares referred to in that announcement.

As at the time of this announcement, Genetic Signatures has not received any approach, proposal or communication from BCAL regarding any strategic transaction, acquisition proposal or other corporate activity involving the Company.

The Board also notes that, at the time of this announcement, no substantial holder notice has been received by the Company or lodged with the ASX in respect of the share acquisition referred to in BCAL’s announcement. The Company expects that any person acquiring a substantial holding will comply with their disclosure obligations under the Corporations Act 2001 (Cth).

Accordingly, Genetic Signatures is not in a position to comment on BCAL’s intentions beyond the statements contained in BCAL’s announcement.

The Board wishes to reassure shareholders, customers, employees and other stakeholders that Genetic Signatures continues to operate in the ordinary course of business. The Company remains fully focused on executing its strategic plan, delivering on its operational and financial objectives, progressing commercial initiatives, supporting customers globally and creating long-term value for shareholders, as outlined in the presentation to the market on 10 June 2026 by CEO, Maria Halasz.

The Company will continue to monitor any developments in this matter and will keep the market informed in accordance with its continuous disclosure obligations should any material information arise.

This announcement has been authorised for release by the Board of Genetic Signatures Limited.

– END –

For further information, see our website (www.geneticsignatures.com) or contact us:

Maria Halasz

Chief Executive Officer

investors@geneticsignatures.com

+61 2 9870 7580

About Genetic Signatures Limited:

Genetic Signatures is a molecular diagnostics company, specialising in detecting infectious diseases, using its patented **3base®** technology to simplify the genetic complexity of pathogen identification. The Company's automated diagnostic workflows accurately screen for multiple infectious pathogens with similar symptoms in a single test. Genetic Signatures' unique solutions enable laboratories to enhance diagnostic workflow and efficiencies, while reducing costs. Rapid results support infection control, appropriate patient management and disease surveillance, improving healthcare outcomes. Genetic Signatures continues to expand its global presence with direct representation in Australia, the United States and Europe, alongside international distribution partnerships.

For personal use only